drugset / Trial / NCT02710214

A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis

NCT02710214 ↗

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Duavee is a hormone receptor modulator that has been approved for the treatment of menopausal symptoms in menopausal women. The goal of this 8-week randomized, double blind, placebo controlled pilot study, is to determine whether this medication alleviates menopausal symptoms in women with MS. The investigators will secondarily determine whether addressing menopausal symptoms ameliorates MS symptoms and, on MRIs, is not triggering worsening inflammation.

Timeline

Start
2016-02
Primary completion
2019-04-24
Completion
2019-04-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Duavee Other / unclassified 0.45 mg —
Subject Duavee Other / unclassified 20 mg —

Indications